Article Details
Retrieved on: 2021-08-12 14:37:30
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
Analysts at JP Morgan resumed their coverage of AstraZeneca at 'overweight', telling clients they saw a "re-rating opportunity". Advertising ...
Article found on: www.sharecast.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here